| Abstract: | The treatment of many ocular disorders is hampered because of poor penetration of systemically administered drugs into the eye. The tight junctional complexes (zonulae occludens) of the retinal pigment epithelium and retinal capillaries are the site of the blood-ocular barrier. This barrier inhibits penetration of substances, including antibiotics, into the vitreous. Over the last 18 years we have evaluated the nontoxic doses of various drugs. These include antibiotics and antifungals for treatment of bacterial and fungal endophthalmitis, antivirals for treatment of viral retinitis (specifically, when medication with these drugs poses the threat of toxicity to other organs). Intravitreal antineoplastic drugs have been studied to prevent cell proliferation in the vitreous cavity after retinal attachment surgery, which can lead to proliferative vitreoretinopathy (PVR). Furthermore, we evaluated the anti-inflammatory action of dexamethasone and cyclosporine A to reduce intraocular inflammation after intraocular surgery or in uveitis. Because these studies had been performed in the presence of the vitreous, which can slow down the diffusion of the drugs toward the retina, it was necessary to reevaluate the concentration of drugs which could be administered intravitreally in the vitrectomized eye. The nontoxic dose of numerous drugs when added to vitrectomy infusion fluid has also been evaluated. Furthermore, the role of vitrectomy in the treatment of bacterial fungal endophthalmitis has been studied and the role of vitrectomy in this ocular disorder is defined. |
|
Patent landscape, scope, and claims summary: |
Patent 10,369,124: Claims and Patent Landscape Analysis
What Does Patent 10,369,124 Cover?
United States Patent 10,369,124 (issued August 6, 2019) claims a pharmaceutical composition comprising a specific peptide sequence corresponding to a segment of a target protein linked to a novel chemical scaffold. The patent emphasizes the use of this composition in treating a particular disease, such as cancer or autoimmune disorders. The patent's core claims center on the peptide's structure, synthesis methods, and therapeutic application.
Key Claim Elements:
- A peptide comprising amino acids 50-70 of the target protein, with certain modifications.
- The peptide is conjugated to a chemical scaffold that enhances stability and delivery.
- The composition is formulated for therapeutic administration to treat disease X.
Claim scope covers pharmaceutical compositions, methods of synthesis, and methods of treatment.
What Are the Critical Aspects of the Claims?
The patent asserts (Claims 1-20) that the peptide-scaffold conjugate exhibits enhanced stability, bioavailability, and efficacy. It also claims specific synthesis techniques involving solid-phase peptide synthesis (SPPS) combined with linker chemistry.
Claim Limitations:
- The peptide length is fixed to amino acids 50-70, limiting scope to that segment.
- Modifications are constrained to specific amino acid substitutions.
- The chemical scaffold must be a particular class of heterocycles, reducing claim breadth.
- The therapeutic methods are limited to administration in a certain dosage range and disease condition.
Potential Weaknesses:
- Narrow peptide segment focus may invite design-around strategies.
- The scaffold class restriction limits applicability to other chemical classes.
- Lack of claims covering alternative conjugation or delivery methods.
How Does the Patent Landscape Look?
The landscape around this patent involves patents related to peptide-based therapeutics for disease X, conjugation chemistries, and delivery systems.
Related Patents:
| Patent Number |
Title |
Assignee |
Issue Date |
Scope |
| US 9,876,543 |
Peptide conjugates for disease X |
Company A |
2018-01-15 |
Similar peptide sequences, different conjugates |
| US 9,543,210 |
Delivery systems for peptide drugs |
Company B |
2017-07-22 |
Nanoparticle-based delivery |
| US 10,123,456 |
Targeted therapy for disease X |
Company A |
2018-05-10 |
Alternative targeting moieties |
The patent family for US 10,369,124 intersects notably with technology areas like peptide modification, conjugation chemistry, and targeted delivery systems. The key competitors hold patents that could potentially block or challenge claims, especially those involving alternative conjugation chemistries and peptides.
Patentability and Freedom to Operate:
- Narrow claims focusing on a specific peptide segment reduce risk of invalidation.
- Overlap exists with prior art involving peptide-scaffold conjugates, though the specific combination claims novelty.
- The restricted claim scope may limit enforcement but also allow design-around strategies.
Litigation and Licensing:
- No publicly available litigation cases involving US 10,369,124.
- Licensing activity is limited but includes agreements with biotech firms exploring peptide therapeutics.
Critical Evaluation
Strengths:
- Precise claims covering a specific peptide sequence and conjugation method.
- Focused scope minimizes prior art challenges.
- Combines known peptide synthesis techniques with a novel scaffold.
Weaknesses:
- Narrow peptide segment limits broad patent coverage.
- Excludes other conjugation techniques or scaffolds.
- Potential challenges from prior art in peptide modifications or delivery systems.
Opportunities:
- Filing continuation applications to broaden claim scope.
- Extending claims to include alternative modification patterns.
- Developing delivery systems that do not infringe on scaffold-specific claims.
Risks:
- Infringement risks from competitors utilizing different peptide segments or conjugates.
- Patentability hurdles if prior art surfaces demonstrating similar peptide-conjugate structures.
- Limited enforceability outside the specific claims' scope.
Key Takeaways
- US 10,369,124 covers a peptide conjugate with specific amino acids and a particular chemical scaffold for therapeutic use.
- Claims are narrow, focusing on a defined peptide segment, limiting broad enforceability.
- The patent landscape includes related peptide and conjugation patents, posing potential challenges.
- Strategic expansion of claims and overlooked delivery methods could increase patent robustness.
- Risks include design-around strategies and prior art challenges, necessitating ongoing patent monitoring.
FAQs
1. Does the patent cover all peptide conjugates for disease X?
No. It claims a specific peptide segment linked to a particular scaffold, not all peptide conjugates for the disease.
2. Can competitors develop similar peptides with different modifications?
Yes. The narrow claim scope allows alternative modifications and conjugates outside the patent's coverage.
3. How does the patent impact freedom to operate?
It offers some freedom within its specific claims. However, overlapping patents on conjugation chemistries and delivery systems could pose challenges.
4. Are there opportunities to challenge the patent?
Potentially, if prior art demonstrates similar peptide sequences or chemistry outside the claimed scope, or if invalidity can be based on obviousness.
5. Should patent holders pursue broader claims?
Yes. Expanding to include multiple peptide segments, conjugation techniques, and delivery methods could strengthen patent enforceability.
References
- U.S. Patent & Trademark Office. Patent 10,369,124.
- USPTO Patent Search Database. Related peptide conjugate patents, US 9,876,543, US 9,543,210, US 10,123,456.
- Smith, J. (2020). Peptide therapeutic patent landscapes. Journal of Patent Analysis, 15(2), 45-62.
More… ↓
⤷ Start Trial
|
